|
1
|
American Cancer Society. Cancer Facts
& Figures 2003. American Cancer Society; Atlanta, GA: 2003
|
|
2
|
Quinn M and Babb P: Patterns and trends in
prostate cancer incidence, survival, prevalence, and mortality.
Part I: international comparisons. BJU Int. 90:162–173. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003.PubMed/NCBI
|
|
4
|
Kaufmann K and Thiel G: Epidermal growth
factor and platelet-derived growth factor induce expression of
Egr-1, a zinc finger transcription factor, in human
malignant glioma cells. J Neurol Sci. 189:83–91. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufmann K and Thiel G: Epidermal growth
factor and thrombin induced proliferation of immortalized human
keratinocytes is coupled to the synthesis of Egr-1, a zinc finger
transcriptional regulator. J Cell Biochem. 85:381–391. 2002.
View Article : Google Scholar
|
|
6
|
Liu C, Rangnekar VM, Adamson E and Mercola
D: Suppression of growth and transformation and induction of
apoptosis by EGR-1. Cancer Gene Ther. 5:3–28. 1998.PubMed/NCBI
|
|
7
|
Parra E, Ferreira J and Saenz L:
Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is
associated with decreased expression of AP-1 and NF-κB. Int J Mol
Med. 28:847–853. 2011.PubMed/NCBI
|
|
8
|
Parra E, Ferreira J and Ortega A:
Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in
prostate carcinoma PC-3 and LNCaP cell lines. Int J Oncol.
39:345–352. 2011.PubMed/NCBI
|
|
9
|
Parra E, Ortega A and Saenz L:
Downregulation of Egr-1 by siRNA inhibits growth of human prostate
carcinoma cell line PC-3. Oncol Rep. 22:1513–1518. 2009.PubMed/NCBI
|
|
10
|
Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee
PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, Homer
RJ and Elias JA: Early growth response gene 1-mediated apoptosis is
essential for transforming growth factor β1-induced
pulmonary fibrosis. J Exp Med. 200:377–389. 2004.PubMed/NCBI
|
|
11
|
Parra E and Ferreira J: The effect of
siRNA- Egr-1 and camptothecin on growth and chemosensitivity of
breast cancer cell lines. Oncol Rep. 23:1159–1165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baron V, Adamson ED, Calogero A, Ragona G
and Mercola D: The transcription factor Egr1 is a direct regulator
of multiple tumor suppressors including TGFβ1, PTEN, p53 and
fibronectin. Cancer Gene Ther. 13:115–124. 2006.PubMed/NCBI
|
|
13
|
Shaul Y and Ben-Yehoyada M: Role of c-Abl
in the DNA damage stress response. Cell Res. 15:33–35. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kharbanda S, Ren R, Pandey P, Shafman TD,
Feller SM, Weichselbaum RR and Kufe DW: activation of the c-Abl
tyrosine kinase in the stress response to DNA-damaging agents.
Nature. 376:785–788. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandey P, Raingeaud J, Kaneli M,
Weichselbaum RR, Davis RJ, Kufe D and Kharbanda S: Activation of
p38 mitogen-activated protein kinase by c-Abl-dependent and
independent mechanisms. J Biol Chem. 271:23775–23779. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cong F and Goff SP: c-Abl-induced
apoptosis, but not cell cycle arrest, requires mitogen-activated
protein kinase kinase 6 activation. Proc Natl Acad Sci USA.
96:13819–13824. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stuart JR, Kawai H, Tsai KK, Chuang EY and
Yuan ZM: c-Abl regulates early growth response protein (EGR1) in
response to oxidative stress. Oncogene. 24:8085–8092.
2005.PubMed/NCBI
|
|
18
|
Daniels CE, Wilkes MC, Edens M, Kottom TJ,
Murphy SJ, Limper AH and Leof EB: Imatinib mesylate inhibits the
profibrogenic activity of TGF-β and prevents bleomycin-mediated
lung fibrosis. J Clin Invest. 114:1308–1316. 2004.PubMed/NCBI
|
|
19
|
Welch PJ and Wang JY: Abrogation of
retinoblastoma protein functions by c-Abl through tyrosine
kinase-dependent and -independent mechanisms. Mol Cell Biol.
15:5542–5551. 1995.PubMed/NCBI
|
|
20
|
Barilà D, Rufini A, Condò I, Ventura N,
Dorey K, Superti-Furga G and Testi R: Caspase-dependent cleavage of
c-Abl contributes to apoptosis. Mol Cell Biol. 23:2790–2799.
2003.PubMed/NCBI
|
|
21
|
Machuy N, Rajalingam K and Rudel T:
Requirement of caspase-mediated cleavage of c-Abl during
stress-induced apoptosis. Cell Death Differ. 11:290–300. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang DY, Chao Y, Tai MH, Yu YH and Lin
WW: STI571 reduces TRAIL-induced apoptosis in colon cancer cells:
c-Abl activation by the death receptor leads to stress
kinase-dependent cell death. J Biomed Sci. 19:352012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li B, Cong F, Tan CP, Wang SX and Goff SP:
Aph2, a protein with a zf-DHHC motif, interacts with c-Abl
and has pro-apoptotic activity. J Biol Chem. 277:28870–28876.
2002.PubMed/NCBI
|
|
24
|
Abdulkadir SA, Carbone JM, Naughton CK,
Humphrey PA, Catalona WJ and Milbrandt J: Frequent and early loss
of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum
Pathol. 32:935–939. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lucerna M, Mechtcheriakova D, Kadl A,
Schabbauer G, Schäfer R, Gruber F, Koshelnick Y, Müller HD,
Issbrücker K, Clauss M, Binder BR and Hofer E: NAB2, a corepressor
of EGR-1, inhibits vascular endothelial growth factor-mediated gene
induction and angiogenic responses of endothelial cells. J Biol
Chem. 278:11433–11440. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parra E: Inhibition of JNK-1 by small
interference RNA induces apoptotic signalling in PC-3 prostate
cancer cells. Int J Mol Med. 30:923–930. 2012.PubMed/NCBI
|
|
27
|
Parra E and Gutiérrez L: Growth inhibition
of Tax-activated human Jurkat leukemia T cells by all-trans
retinoic acid requires JNK-1 inhibition. Oncol Rep. 29:387–393.
2013.PubMed/NCBI
|
|
28
|
Krones-Herzig A, Mittal S, Yule K, Liang
H, English C, Urcis R, Soni T, Adamson ED and Mercola D: Early
growth response 1 acts as a tumor suppressor in vivo and in vitro
via regulation of p53. Cancer Res. 65:5133–5143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calogero A, Arcella A, De Gregorio G,
Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G,
Gagliardi FM, Caruso R, Gulino A, Frati L and Ragona G: The early
growth response gene EGR-1 behaves as a suppressor gene that
is down-regulated independent of ARF/Mdm2 but not p53 alterations
in fresh human gliomas. Clin Cancer Res. 7:2788–2796. 2001.
|
|
30
|
Egerod FL, Bartels A, Fristrup N, Borre M,
Ørntoft TF, Oleksiewicz MB, Brünner N and Dyrskj⊘t L: High
frequency of tumor cells with nuclear Egr-1 protein expression in
human bladder cancer is associated with disease progression. BMC
Cancer. 9:3852009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Svaren J, Ehrig T, Abdulkadir SA,
Ehrengruber MU, Watson MA and Milbrandt J: EGR1 target genes in
prostate carcinoma cells identified by microarray analysis. J Biol
Chem. 275:38524–38531. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gitenay D and Baron VT: Is EGR1 a
potential target for prostate cancer therapy? Future Oncol.
5:993–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki J, Sukezane T, Akagi T, Georgescu
MM, Ohtani M, Inoue H, Jat PS, Goff SP, Hanafusa H and Shishido T:
Loss of c-abl facilitates anchorage-independent growth of
p53- and RB-deficient primary mouse embryonic fibroblasts.
Oncogene. 23:8527–8534. 2004.
|
|
34
|
Taagepera S, McDonald D, Loeb JE, Whitaker
LL, McElroy AK, Wang JY and Hope TJ: Nuclear-cytoplasmic shuttling
of C-ABL tyrosine kinase. Proc Natl Acad Sci USA. 95:7457–7462.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ling X, Ma G, Sun T, Liu J and Arlinghaus
RB: Bcr and Abl interaction: oncogenic activation of c-Abl by
sequestering Bcr. Cancer Res. 63:298–308. 2003.PubMed/NCBI
|
|
36
|
Furstoss O, Dorey K, Simon V, Barilà D,
Superti-Furga G and Roche S: c-Abl is an effector of Src for growth
factor-induced c-myc expression and DNA synthesis. EMBO J.
21:514–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baron V, De Gregorio G, Krones-Herzig A,
Virolle T, Calogero A, Urcis R and Mercola D: Inhibition of Egr-1
expression reverses transformation of prostate cancer cells in
vitro and in vivo. Oncogene. 22:4194–4204. 2003. View Article : Google Scholar : PubMed/NCBI
|
